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55 patients with advanced cutaneous squamous cell carcinoma (CSCC) of the trunk and extremities were studied. A Tissue
Microarray was constructed using immunohistochemistry to quantify expression of the HER family, E-cadherins, and podoplanin.
Clinical and histopathological factors related to lymph node metastasis and prognosis were also established. Primary tumor
positivitywas25.5%forEGFR,87.3%forHER-3,and48.1%forHER-4.MetastaseswerepositiveforEGFRin41.7%,forHER-3in
83.3%, and HER-4 in 43.5%. HER-2 was negative in all samples. Membrane E-cadherin and cytoplasmic E-cadherin were positive
in 47.3% and 30.2% of primary tumors and 45.5% and 27.3% of metastases, respectively. Podoplanin was positive in 41.8% of
primary tumors and 41.7% of metastases. Intratumoral lymphocytic inﬁltrate was associated with lymph node metastasis. Patients
withT3tumorshadbettercancer-speciﬁcsurvival(CSS)thanthosewithT4tumors;patientswithnolymphnodeinvolvementhad
better CSS than patients with N1 tumors. Undiﬀerentiated tumors and hyperexpression of podoplanin were negative prognostic
indicators on multivariate analysis.
1.Introduction
“Locally advanced cutaneous squamous cell
carcinoma of the trunk and extremities has a
poor prognosis. Thisstudy identiﬁed prognostic
factors including podoplanin, a novel molecular
marker.”
Cutaneous squamous cell carcinoma (CSCC) has a high
incidence worldwide particularly in the sun exposed skin
of Caucasians [1–5]. The majority of cases are readily
treatable by simple excision or radiotherapy with a good
chance of achieving cure. However, locally advanced tumors
may present with local recurrence, lymph node or distant
metastasis [6–12]. Unlike head and neck tumors, where the
presence of lymph node metastases and disease progression
are more common, Prognostic factors for advanced tumors
of the trunk and extremities are not well established. Clinical
and epidemiologic factors are poorly understood with only
a few reports in the literature [10, 11, 13–15]. Knowledge
of the role of molecular markers in tumor progression and
metastasis is limited. The tyrosine kinases Human Epidermal
Receptor (HER) family (Epidermal Growth Factor Receptor
(EGFR), HER-2, HER-3, and HER-4) are transmembrane
glycoproteinsrelatedtocellproliferation,diﬀerentiation,and
apoptosis [16]. Altered expression of the HER family is asso-
ciatedwithseveralepithelialtumorssuchasbreastcarcinoma2 Journal of Skin Cancer
and esophageal squamous cell carcinoma [17–20]. Small
studies have also shown altered HER expression in localized
squamous cell carcinoma when compared to normal skin
[21–24]. HER expression in advanced CSCC of the trunk
and extremities is not well studied and may be related to
prognosis allowing the use of targeted therapies that block
the HER pathway.
E-cadherin is a transmembrane glycoprotein, and it
is a mediator of calcium-dependent cell-cell adhesion in
normal cells [25]. Reduced cell-cell adhesiveness is con-
sidered important in both early and late carcinogenis [25,
26]. High E-cadherin expression in cell cytoplasm and low
expression in the cell membrane are associated with tumor
aggressiveness in diﬀerent cancers, (i.e., lung cancer).
Podoplanin is a membrane protein found on lym-
phatic vessel endothelium. Its function is poorly understood
although it may govern endothelial motility, and its absence
in animal studies is associated with lymphedema and
malformationoflymphaticvessels[27].Theaimofthisstudy
was to determine the expression of markers such as the HER
family, E-cadherin, and Podoplanin in a consecutive series of
locally advanced CSCC of the trunk and extremities and to
deﬁne clinical, pathological, and molecular factors related to
lymph node metastasis and survival.
2. Methods
A retrospective study of patients with locally advanced
(American Joint Committee on Cancer staging T3 and T4 )
CSCC of the trunk and extremities admitted to two cancer
institutions in Brazil (Barretos Cancer Hospital and Amaral
Carvalho Hospital) between 1997 and 2006 was performed.
Only those patients with tumor paraﬃn blocks available for
analysis were included. Patients with tumor inﬁltration of
the head and neck or genital area and those with a previous
cancer diagnosis other than cutaneous basal cell carcinoma
were excluded. This was to avoid diﬃculties in identifying
origin of metastasis and cause of death. 55 consecutive
patients admitted and treated from October 1997 to March
2006withapathologicdiagnosisofsquamouscellcarcinoma
were evaluated. Patients had to have stage T3 (tumor >5cm)
or T4 (invasive of deep extradermal structures) tumors
according to the 2002 American Joint Committee on Cancer
(AJCC) staging system. Institutional Review Board approval
was obtained and all clinical information retrospectively
collected from medical records.
2.1. Demographic and Clinical Characteristics. Demographic
andclinicalvariablesassessedincludedage,gender,ethnicity,
previous chronic skin lesions (burns, scars, varicose ulcers
and others) at the site of the tumor, patient residence (rural
or urban), anatomic site, and treatment. Patterns of lymph
node metastases, recurrence, and survival outcomes were
also recorded.
Lymph node metastasis was classiﬁed as follow: N0:
patients with no evidence of lymph node metastasis at
presentation; N1: patients with lymph node metastasis
at presentation. We considered lymph node metastasis at
presentation (N1) or recurrence as the endpoint for risk
of lymph node metastasis. The endpoint for survival was
death from cancer. Only clinically involved lymph nodes
were removed and no elective or sentinel node dissections
were performed.
2.2. Pathology. 55 primary tumors and 22 lymph node
metastases were available for pathological review by two
pathologists. The pathological variables analyzed were num-
ber of mitosis/mm2, deepest tumor diameter (Breslow
depth), tumor grade I to III as previously described [28],
perineural or perivascular inﬁltration, and intratumoral
and peritumoral lymphocytic inﬁltration. Any lymphocytic
inﬁltration was quantiﬁed as positive. Breslow depth was
available in 44 cases.
2.3. Tissue Micro array. After pathological review, the most
representative tumor area in the paraﬃn block was selected
for creation of a tissue microarray (TMA). Both primary
tumors and lymph node metastases were selected. A Manual
Tissue Arrayer I, (Beecher Instruments, EUA) was used
to obtain two cylinders of 1.0 millimeter in diameter
from each paraﬃn bloc. These were implanted into the
receptor paraﬃn block (TMA). Fifty slides were obtained
and numbered from the TMA. For sample quality analysis
slide numbers 1, 25, and 50 were stained with hematoxilin
and eosin, and the most representative was chosen, and the
other slides studied were subsequent to this.
2.4.Immunohistochemistry. Deparaﬃnizationofthesections
was done with xylene for 15 minutes at 60◦C, followed by
15 minutes at room temperature. The sections were then
washed 3 times for 30 seconds with 100%, 95%, 80%,
and 70% ethanol before washing in water. Endogenous
peroxidase was blocked by incubating the sections in 6%
hydrogen peroxide in methanol. The sections were then
washed with phosphate buﬀered saline (PBS) 10mM pH 7.4
for 5 minutes. Incubation followed, as described by Hsu and
Raine [29] with the speciﬁc antibody diluted in PBS with
1.0% bovin serum albumin (Sigma USA) and 0.1% NaN3 for
30 minutes at 37◦Ca n df o r1 6h o u r sa t4 ◦C.
For EGFR the H11 clone (DAKO) was used, diluted
1:1 0 0i na na u t o c l a v ew i t hE D T Aa tp H8 . 0 .T h ef o l l o w i n g
HER family polyclonal antigens were used all with citrate
at pH 6.0: HER-2 (DAKO) diluted 11500 in a moist cham-
ber, HER-3 (Neomarkers) 1:100 in an autoclave, (HER-4)
(Neomarkers) 1:300 in an autoclave. The E-cadherin NCH-
38 (DAKO) monoclonal antigen was diluted 1:600 in a
moist chamber with EDTA/TRIS at pH 9.0. The Podoplanin
D2–40 clone (DAKO) was used at a dilution of 1:200
in a moist chamber with EDTA/TRIS at pH 9.0. After
incubation they were washed with PBS 3 times for 5
minutes each and then antigen ampliﬁcation was performed.
After ampliﬁcation they were again washed with PBS 3
times for 5 minutes each. Reactions were visualized with
0.6mg/mL 3 -3  diaminobencidine tetrahydrochloride and
0.06%hydrogenperoxideina1%PBSsolutionfor5minutes
at 37◦C. The ﬁnal reaction was a brown color deposit in the
cell area where the antigen-antibody reaction had occurred.Journal of Skin Cancer 3
Table 1: Demographic, clinical, therapeutic, and pathological characteristics of patients with locally advanced cutaneous squamous cell
carcinoma of trunk and extremities.
Characteristics n (%) Characteristics n (%)
Gender Lymph node metastasis location
Male 32 (58.2) Axila 15 (60.0)
Female 23 (41.8) Groin 10 (40.0)
Race Lymph node metastasis treatment
Caucasian 49 (89.1) Linphadenectomy 28 (93.3)
African 6 (10.9) No treatment 2 (6.7)
Residence Local or lymph node recurrence after lymphadenectomy
Rural 9 (16.4) No 13 (46.4)
Urban 46 (83.6) Local 8 (28.6)
Lymph node 7 (25.0)
Chronic sun exposure Distant metastasis
Yes 27 (49.1) No 58 (92.1)
No 12 (21.8) Cutaneous 1 (1.6)
n.a. 16 (29.1) Visceral 4 (6.3)
Anatomical localization Lymph node metastasis treatment
Lower extremities 22 (40.0) Linphadenectomy 24 (96.0)
Upper extremities 23 (41.8) No treatment 1 ( 4.0)
Trunk 10 (18.2)
Non-cancer previous lesion Tumor grade
Yes 13 (23.6) I 25 (45.5)
No 42 (76.4) II 27 (49.0)
III 3 (5.5)
T classiﬁcation Intratumoral lymphocitic inﬁltrate
T3 33 (60.0) Negative 12 (21.8)
T4 22 (40.0) Positive 43 (78.2)
N classiﬁcation Peritumoral lymphocitic inﬁltrate
N0 41 (74.5) Negative 9 (16.4)
N1 14 (25.5) Positive 46 (83.6)
Clinical stage Vascular inﬁltrate
II 27 (49.1) Negative 48 (87.3)
III 28 (50.9) Positive 7 (12.7)
Treatment of primary tumor Perineural inﬁltrate
surgery Negative 54 (98.2)
Local resection with primary closure 1 ( 1.9) Positive 1 (1.8)
Local resection with reconstruction 18 (32.7)
Amputation/disarticulation 21 (38.2)
Local resection with open wound 5 ( 9.1)
Radiation therapy 8 (14.5)
No treatment 2 (3.6)
n.a.: not available.
2.5. Immunohistochemistry Expressions. The EGFR, HER-3,
and HER-4 expressions were evaluated semiquantitatively
according to the method described by Lager et al. [30]. Areas
with more intense reaction were selected, and the intensity
of cytoplasm and/or membrane reaction was classiﬁed as 0
negative; + weak; ++ moderate; +++ intense. For the study,
tumors classiﬁed as 0 or + were considered negative and
tumors classiﬁed as ++ or +++ were considered positive.
HER-2 expression was evaluated semiquantitatively
according to the intensity of reaction in the cytoplasmatic
membrane. Negative or weak reaction in less than 10% of
cells was classiﬁed as “0”, weak reaction in more than 10%
as “+”, moderate reaction in more than 10% as “++”, and
strong reaction in more than 10% as “+++” positivity. For
the analysis, 0 and + were considered negative and ++ and
+++ positive [31].4 Journal of Skin Cancer
Table 2: Univariate analysis of risk factors for lymph node metastasis in patients with locally advanced cutaneous squamous cell carcinoma
of trunk and extremities.
Variables + Lymph node metastasis n (%) − Lymph node metastasis n (%) p
Clinical
Gender
Male 16 (64.0%) 16 (53.3%) 0.584
Female 9 (36.0%) 14 (46.7%)
Race
Caucasian 22 (88.0%) 27 (90.0%) 1.000
African 3 (12.0%) 3 (10.0%)
Ambient
Rural 4 (16.0%) 5 (16.7%) 1.000
Urban 21 (84.0%) 25 (83.3%)
Chronic Sun exposure
Yes 14 (66.7%) 13 (72.2%) 0.742
No 7 (33.3%) 5 (27.8%)
Anatomic location of primary tumor
Lower extremities 8 (32.0%) 14 (46.7%)
0.151 Upper extremities 14 (56.0%) 9 (30.0%)
Trunk 3 (12.0%) 7 (23.3%)
Previous non neoplasic lesion
Yes 7 (72.0%) 6 (20.0%) 0.537
No 18 (28.0%) 24 (80.0%)
TNM Classiﬁcation
T3 13 (52.0%) 20 (66.7%) 0.286
T4 12 (48.0%) 10 (33.3%)
Tumor length∗
Breslow 0–8mm 14 (56.0%) 8 (44.5%) 0.533
Breslow >8mm 10 (44.0%) 10 (55.5%)
Mitosis/mm2
0–3 22 (44.9%) 27 (55.1%) 0.573
>3 3 (50.0%) 3 (50.0%)
Tumor grade
I 11 (44.0%) 14 (46.6%) 1.000
II-III 14 (56.0%) 16 (53.4%)
Intratumoral lymphocitic inﬁltrate
Negative 2( 8 . 0 %) 10 (33.4%) 0.046
Positive 23 (92.0%) 20 (66.6%)
Peritumoral lymphocitic inﬁltrate
Negative 2 (8.0%) 7 (23.4%) 0.160
Positive 23 (92.0%) 23 (76.6%)
Vascular inﬁltrate
Negative 20 (80.0%) 28 (93.3%) 0.226
Positive 5 (20.0%) 2 ( 6.7%)
Perineural inﬁltrate
Negative 24 (96.0%) 30 (100.0%) 0.455
Positive 1 (4.0%) 0 (0.0%)
Tumor markers
EGFR
Negative 17 (68.0%) 24 (80.0%) 0.363
Positive 8 (32.0%) 6 (20.0%)
HER-2
Negative 25 (100%) 30 (100%) Not calculated
Positive 0 0Journal of Skin Cancer 5
Table 2: Continued.
Variables + Lymph node metastasis n (%) − Lymph node metastasis n (%) p
HER-3
Negative 1 (4.0%) 6 (20.0%) 0.112
Positive 24 (96.0%) 24 (80.0%)
HER-4
Negative 16 (65.0%) 12 (41.4%) 0.083
Positive 9 (35.0%) 17 (59.6%)
Membrane E-cadherin
Negative 12 (54.5%) 14 (46.7%) 0.779
Positive 10 (45.5%) 16 (53.3%)
Cytoplasm E-cadherin
Negative 17 (73.9%) 20 (46.6%) 0.764
Positive 6 (26.1%) 10 (63.4%)
Podoplanin
Negative 13 (52.0%) 19 (63.3%) 0.425
Positive 12 (48.0%) 11 (36.7%)
∗Only 42 cases.
Cytoplasmic and membranous E-cadherin immunoex-
pressions were semiquantitatively evaluated as negative if
the reaction occurred in up to 50% of cells and positive if
occurred in more than 50% of cells.
The podoplanin (D2–40) immunoreactivity was semi-
quantitatively evaluated as described by Padgett et al. [32]:
negative: no reactivity or weak reaction independently of the
number of cells or moderate/strong reaction in up to 10% of
cells; positive: moderate or intense immunoreaction in more
than 10% of cells.
2.6. Statistics. To analyze the association between clinical
variables and lymph node metastasis the chi square, Fisher
exact, and t-test were used. Speciﬁc Cancer Survival (SCS)
was also studied, and curves were constructed using the
Kaplan-Meier method and compared using the univariate
log-rank test. All tests were two sided, and a P-value of
≤.05 was considered statistically signiﬁcant. Simultaneous
prognostic eﬀect of various factors was determined in a
multivariate analysis by use of the Cox proportional-hazards
regression model with a covariate of primary interest and
adjustment covariates.
3. Results
3.1.Demographic,Clinical,andPathologicalDescriptiveChar-
acteristics. 55 patients with a Mean age of 63 years (Range
30–91) were included in the study.
The median number of mitosis/mm2 was 3 and median
Breslowdepthwas8mm.Tumorcharacteristicsareshownin
Table 1.
3.2. Immunohistochemistry. EGFR positivity was 25.5% in
the primary tumor and 41.7% in the metastases. HER-2
was negative in all samples. HER-3 and HER-4 positivity
was 87.3% and 48.1% in the primary tumor and 83.3%
and 43.5% in the metastases, respectively. Membrane E-
cadherin positivity was 47.3% in the primary tumor and
27.3% in the metastases. Primary tumor cytoplasmic E-
cadherin was positive in 30.2% and 45.5% in the metastasis.
The E-cadherin membrane/cytoplasmic ratio was 1.56 in
the primary tumor and 0.60 in the metastases. Podoplanin
positivity was 41.8% in primary tumor and 41.7% in
metastases.
3.3. Risk of Lymph Node Metastasis. Intratumoral lympho-
cytic inﬁltrate was the only prognosticator of lymph node
metastasis (92% versus 66.6%; p = 0.046) (Table 2).
3.4. Survival. The mean and median followup was 9.6 (SD
25.0) and 25.0 months, respectively. At last followup, 19
patients were alive with no evidence of disease (34.5%),
one was alive with disease (1.8%), 19 were dead of disease
(34.5%), 9 dead from other causes (16.4%), and 7 lost
to followup (12.7%). Those lost to followup had a mean
and median followup of 24.5 (SD 21.8) and 22.1 months
respectively. Only two patients were followed up for less than
one year and three patients for less than 22 months. For
the 11 patients that presented with lymph node metastasis
during the followup, median time to occurrence was 13.08
months.
The overall ﬁve years cancer-speciﬁc survival (CSS) was
49.7%. For patients with T3 tumors 5-year CSS was 67.6%,
and no patients with T4 tumors were alive at 5 years
(p = 0 .001). Patients with no lymph node metastases
had a 5-year CSS of 63.3%, with no 5 year survivors in
patients with lymph node metastases (p = 0.004). Gender,
race, ambient, anatomic location, location of metastasis,
and presence of previous nononcologic lesions did not
aﬀect survival (Table 3). There was no diﬀerence in 5-
year CSS between patients with primary tumors with up
to 3mitosis/mm2 and those with more than 3 mitosis6 Journal of Skin Cancer
Table 3: Comparative speciﬁc cancer survival rates according to clinical variables in patients with locally advanced cutaneous squamous cell
carcinoma of trunk and extremities.
Variable Five years survival (%) S.E. p
Gender
Male 42.9 11.3 0.172
Female 64.8 16.0
Race
Caucasian 50.2 10.8 0.443
African 44.4 22.2
Ambient
Rural 71.4 17.1 0.598
Urban 46.0 11.1
Chronic Sun exposure
Yes 47.5 11.5 0.972
No 00.0 00.0
Anatomic location of primary tumor
Lower extremities 61.0 15.5
0.441 Upper extremities 38.7 15.1
Trunk 55.6 16.6
Lymph node metastasis location
Axila 28.1 15.6 0.858
Groin 00.0 00.0
Previous non neoplasic lesion
Yes 39.1 18.6 0.221
No 54.3 11.2
TNM Classiﬁcation
T3 67.6 10.8 0.001
T4 00.0 00.0
Lymph node status
N0 63.3 10.9 0.004
N1 00.0 16.8
Clinical stage
II 84.3 7.2 <0.001
III 00.0 00.0
(49.7% versus 47.2%, p = 0 .375). No signiﬁcant diﬀerence
in 5-year CSS was seen for Breslow depth, peritumoral
lymphocytic inﬁltrate, vascular, and perineural inﬁltration.
The only histological variable that had a signiﬁcant impact
onsurvivalwasthetumorgrade.PatientswithgradeIlesions
had a 5-year CSS of 82.2% compared with 23.8% in patients
w i t hg r a d eI Ia n dI I It u m o r s( p = 0 .010). Podoplanin
negative patients had a higher 5 years (Figure 1, Table 4).
In metastatic tumors, HER-4 negativity resulted in a 3-
year CSS of 66.7% versus 37.5% in HER-4 positive patients
(p = 0 .038). Clinical stage and Podoplanin positivity
were independent prognostic factors on both univariate and
multivariate analysis (Table 5).
4. Discussion
4.1. Demographics and Clinical Characteristics. Previous
nonskin cancer lesions at the site of disease were seen in
23% of patients. Although not associated with lymph node
metastasisorpoorprognosis,unlikepreviousreports[6],the
presence of noncancerous skin lesions may result in locally
advanced disease due to mis- or delayed diagnosis. The T
stage of tumor strongly inﬂuenced survival but not incidence
of lymph node metastasis. The high number of N1 patients
(25.5%) has been previously described in an identical setting
[10], and may be associated with the two Hospitals involved
being tertiary referral oncology centers.
4.2. Pathological Characteristics. Intratumoral lymphocytic
inﬁltration was associated with lymph node metastasis. The
inﬂammatory response may lead to greater tumor antigen
exposure in the metastatic lymph node. Tumor thickness
(Breslow) had no impact on lymph node metastasis and
did not inﬂuence survival. Breslow depth may correlate with
lymph node metastasis and survival in less advanced tumors,
but in this study median tumor thickness was high whichJournal of Skin Cancer 7
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Table 4: Comparative speciﬁc cancer survival rates according to
immunohistochemical primary tumor expression in patients with
locally advanced cutaneous squamous cell carcinoma of trunk and
extremities.
Variable 5-year survival (%) S.E. p
EGFR
Negative 52.1 10.8 0.592
Positive 34.6 25.3
HER-2
Negative All cases negative
Positive
HER-3
Negative 0.0 0.0 0.231
Positive 52.5 10.3
HER-4
Negative 49.6 12.4 0.632
Positive 44.0 17.0
Membrane E-cadherin
Negative 38.3 12.7 0.112
Positive 65.5 13.9
Cytoplasm E-cadherin
Negative 35.6 12.5 0.296
Positive 72.5 11.8
Podoplanin
Negative 71.9 10.1 0.018
Positive 23.5 13.2
may have weakened any association. Low-grade tumors were
associated with prolonged survival conﬁrming the aggressive
nature of undiﬀerentiated tumors.
Table 5: Multivariate Cox regression model for speciﬁc cancer
survival in patients with locally advanced cutaneous squamous cell
carcinoma of trunk and extremities.
Variable HR 95% CI p
Clinical stage
II 1 0.003
III 5.903 1.861–18.728
Podoplanin
Negative 1 0.050
Positive 2.839 1.011–8.128
Age 1.010 0.978–1.044 0.543
Treatment
Surgery 1 0.978
Radiotherapy 0.981 0.254–3.785
4.3. Molecular Markers. Unlike squamous cell carcinoma of
the head and neck or esophagus, EGFR had no inﬂuence on
prognosis. It is possible that altered EGFR expression may
be associated with local recurrence, which is more frequently
life threatening at other sites. HER-2 was negative in all
samples and may play little part in CSCC progression as
found in squamous cell carcinomas from other sites. High
HER-4 expression in lymph node metastases was associated
withpoorprognosissuggestingaroleinprogressionofCSCC
of the trunk and extremities. It is possible that altered HER-
4 expression occurs late and is present only in metastases.
The altered coexpression of the HER family may play a
role (i.e., EGFR/HER-4, HER-3/HER-4, and EGFR/HER-
3/HER-4) but the small number of cases in this study
meant this could not be analyzed. E-cadherin expression
had no signiﬁcant association with lymph node metastasis
or survival, but the expression ratio between membrane
and cytoplasm was lower in the metastasis, suggesting
accumulation with a loss of function. This may be due to a
mutated E-cadherin resulting in cytoplasmic accumulation
with a loss of cell adhesion and disease progression [33, 34].
Some studies have looked at the membrane expression of E-
cadherin in cutaneous squamous cell carcinoma compared
with normal skin, local tumors, and metastasis, suggesting a
progressive loss of expression [35–37].
Podoplanin expression was not associated with the
presence of lymph node metastasis, but was a prognosticator
of reduced survival indicating a locally aggressive tumor,
with survival impact. Altered expression of podoplanin is
associated with mesothelioma, squamous cell carcinoma
of oral mucosa, and germ cell tumors, suggesting that
podoplanin may inﬂuence invasive and proliferative activ-
ity [38–40]. As CSCC metastases occur preferentially via
lymphatic vessels, podoplanin expression may be associated
with disease progression. Hyperexpression has been related
to undiﬀerentiated skin tumors, but its impact on prognosis
and metastasis has not been established [41]. Podoplanin is
a possible target for development of novel therapies, and its
expression has to be studied in other settings to completely
understand its role in cancer development and progression.8 Journal of Skin Cancer
Patients with advanced CSCC of trunk and extremities
withpoorprognosticfactorssuchasundiﬀerentiated,T4,N1
tumors, high podoplanin expression in the primary tumor,
or high HER-4 expression in the lymph node metastasis
may be candidates for new more aggressive modalities of
treatment. Further studies using these molecular markers are
needed to help reﬁne treatment of CSCC of the trunk and
extremities.
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